[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f3pvvtt2ft5r8w":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"proprietary_name":11,"non_proprietary_name":11,"is_proprietary":11,"active_ingredient":12,"administration_route":13,"available_strength":11,"dosage_form":14,"dose_schedule":15,"drug_unit":11,"is_available_generically":11,"mechanism_of_action":16,"overdosage":17,"warning":18,"species":19,"citations":20,"dose_schedules":34,"available_strengths":35,"label_statements":36,"drug_classes":37,"specialties":48,"medical_conditions":49,"animal_species":50},1889,"rdh7qy1xpu3xo0qw0qbwtkvz","tolfenamic-acid","tolfenamic acid",null,"Each ml contains:\r \r Active substance 40mg\r Tolfenamic acid\r \r Excipients\r \r Benzyl alcohol 10.4mg\r \r Sodium formaldehyde sulphoxylate 5mg\r \r For a full list of excipients, see section 6.1","intramuscular, oral, subcutaneous","Sterile solution for injection\r A clear colourless to slightly yellow sterile aqueous solution","The recommended dose is 4 mg\u002Fkg bodyweight.","Tolfenamic acid (N-(2-methyl-3-chlorophenyl) anthranilic acid) is a non-steroidal anti-\r\ninflammatory drug belonging to the fenamate group. Tolfenamic acid possesses anti-\r\n\r\n Page 3 of 6\r\n\f Revised: December 2025\r\n MA split from NI Expiry following AN: 03286\u002F2025\r\n\r\ninflammatory, analgesic and antipyretic properties.\r\n\r\nThe anti-inflammatory activity of tolfenamic acid is due to inhibition of\r\ncyclooxygenase leading to a reduction in prostaglandin and thromboxane synthesis,\r\nmajor inflammatory mediators.","In case of overdose, administer a symptomatic treatment.","NSAIDS can cause inhibition of phagocytosis and hence in the treatment of\r\ninflammatory conditions associated with bacterial infections appropriate concurrent\r\nantimicrobial therapy should be instigated\r\n\r\nThe use of insulin-type needle\u002Fsyringe is advisable particularly in low-weight animals\r\nto ensure an accurate dose.",[],[21],{"covers":22,"source":30,"licence":31,"source_url":32,"retrieved_at":33},[23,24,25,26,27,28,29],"active_ingredient","administration_route","dosage_form","dose_schedule","mechanism_of_action","overdosage","warning","UK VMD Summary of Product Characteristics","Crown copyright, Open Government Licence v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002FProductInformationDatabase\u002Ffiles\u002FSPC_Documents\u002FSPC_121515.PDF","2026-09-20",[],[],[],[38,43],{"id":39,"documentId":40,"slug":41,"name":42},972,"viq37v13vex666st2k3tarm2","anti-inflammatory-and-anti-rheumatic-products-non-steroids","Anti-inflammatory and anti-rheumatic products, non-steroids",{"id":44,"documentId":45,"slug":46,"name":47},987,"acpnknbmsal5y7mvh4xrb9ac","fenamates","Fenamates",[],[],[]]